HEALTH● LOWSep 26 · Sep 26, 2026, 3:07 PM
Dr Voorhees on the Mechanism of Action of Etentamig in Multiple Myeloma
onclive · united states of america · global
Peter Voorhees, MD, discusses CRS and infection data for etentamig from the phase 3 CERVINO trial in triple-class–exposed relapsed/refractory myeloma.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
See it on the live mapunited states of america and nearby eventsMore from united states of americaLatest stories and threat level
More in Health
HEALTH1h agoLongevity-first healthcare takes spotlight at Abu Dhabi Future Health SummitSouth China Morning PostHEALTH2h agoKenya’s Ebola cases test preparedness beyond NairobiAl Jazeera [en]HEALTH3h agoEven after explosive diarrhea outbreak Trump’s FDA looks to ease food requirementsThe Independent WorldHEALTH5h agoPope Leo recovers after lung surgeryNBC News